IM Reports Results of IMT-002 in P-Ib MAD Trial for the Treatment of Type 1 Diabetes
Shots:
- The P-Ib MAD trial involves assessing IMT-002 (350 /1050 mg- qd/bid over a 2wks.) vs PBO in 30 T1D patients preselected for HLA-DQ8 aged b/w 18-45yrs. and were interspersed in the 4 groups and involves a 1wk. follow-up after dose completion
- The therapy was safe & well-tolerated with no SAEs & did not increase with dose. PK were followed for (1050mg- qd) & (350/700/1050mg- bid) over 24-hrs. after drug administration- IMT-002 (bid regimen) showed increase in Cmax & high Ctrough @4hrs. while qd dose showed low Cmax & Ctrough
- IMT-002 targets HLA-DQ8 to prevent the immune system from attacking insulin-producing beta cells. The company is planning to advance the therapy in the P-II study
| Ref: Businesswire | Image: IM Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com